Leuprolide Acetate (LA)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Central Precocious Puberty (CPP)
Conditions
Central Precocious Puberty (CPP)
Trial Timeline
Oct 24, 2018 → Nov 29, 2023
NCT ID
NCT03695237About Leuprolide Acetate (LA)
Leuprolide Acetate (LA) is a phase 3 stage product being developed by AbbVie for Central Precocious Puberty (CPP). The current trial status is completed. This product is registered under clinical trial identifier NCT03695237. Target conditions include Central Precocious Puberty (CPP).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03695237 | Phase 3 | Completed |
Competing Products
20 competing products in Central Precocious Puberty (CPP)